A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection | Zendy

David A. Talan | Zendy; Frank LoVecchio | Zendy; Fredrick M. Abrahamian | Zendy; David J. Karras | Zendy; Mark T. Steele | Zendy; Richard E. Rothman | Zendy; Anusha Krishnadasan | Zendy; William R. Mower | Zendy; Rebecca Hoagland | Zendy; Gregory J. Moran | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection

Author(s) -

David A. Talan,

Frank LoVecchio,

Fredrick M. Abrahamian,

David J. Karras,

Mark T. Steele,

Richard E. Rothman,

Anusha Krishnadasan,

William R. Mower,

Rebecca Hoagland,

Gregory J. Moran

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw177

Subject(s) - medicine , clindamycin , trimethoprim , sulfamethoxazole , confidence interval , adverse effect , population , randomized controlled trial , antibiotics , surgery , staphylococcus aureus , microbiology and biotechnology , biology , genetics , environmental health , bacteria

With the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) in the United States, visits for skin infections greatly increased. Staphylococci and streptococci are considered predominant causes of wound infections. Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed, but the efficacy of TMP-SMX has been questioned.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research